New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
09:05 EDTHZNPHorizon Pharma's RAYOS 5mg reduced morning stiffness in patients with RA
Horizon Pharma announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2, or CAPRA- 2, trial demonstrating that patients with active rheumatoid arthritis, or RA, treated with its recently approved RAYOS 5 mg delayed-release tablets who met ACR20, DAS28 and HAQ-DI response criteria had a significantly greater reduction in morning stiffness than patients who didn't meet these criteria. Data were presented during the American College of Rheumatology, or ACR/Association of Rheumatology Health Professionals, or ARHP, Annual Scientific Meeting in Washington, D.C. Results from these analyses demonstrated that morning stiffness duration, morning stiffness severity and pain intensity upon awakening correlated with DAS28 and HAQ-DI in all treatment group analyses. There were stronger absolute correlations seen with morning stiffness severity and pain intensity upon awakening than with morning stiffness duration, whether the treatment groups were analyzed separately or together. Patients who met ACR20, DAS28 and HAQ-DI response criteria had a greater relative reduction in morning stiffness than patients who didn't meet these criteria. There were no safety concerns for RAYOS 5 mg shown in the study beyond those already established for immediate-release prednisone.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
07:31 EDTHZNPHorizon announces early termination of HSR waiting period for Vidara acquisition
Subscribe for More Information
April 14, 2014
11:09 EDTHZNPOptions with increasing implied volatility: HZNP VJET YOKU CTRX CBS
April 11, 2014
10:35 EDTHZNPHigh option volume stocks: HZNP NI IPG CYTR SNV NBR
Subscribe for More Information
April 10, 2014
07:35 EDTHZNPHorizon Pharma announces patent allowance from USPTO
Horizon Pharma announced that Skyepharma has received a Notice of Allowance from the United States Patent and Trademark Office, or USPTO, for U.S. Patent Application 13/713,528 entitled "Delayed-Release Tablet with Defined Core Geometry" that covers the Company's U.S. approved product RAYOS. This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2024. After issuance, Horizon plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the fifth U.S. patent to be listed in the Orange Book for RAYOS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use